Episode Details

Shadd Dales digs into a big win in the cannabis industry, with special guest Aras Azadian from Avicanna Inc. (TSX: AVCN). The company just had its best year yet, hitting $25.5 million in revenue—a massive 52% jump from the year before. Aras shares what fueled this success and what’s next for Avicanna in 2025.We breakdown key metrics that included improved gross margins, up to 51%, and the 94% surge in gross profits. The discussion also touches on the company’s efforts in reducing its adjusted EBITDA loss by 68%, signaling a strong move toward profitability.Plus, we discuss the podcast explores Avicanna’s global expansion strategy, its key priorities for 2025 and 2026, and the recent news about delays in financial filings. This is an episode that includes latest cannabis trends, the international medical marijuana opportunity, and and market insights.0:00:00 - Intro0:01:07 - Discussion of Avicanna's best year and medical business model0:04:04 - International medical cannabis opportunities0:08:06 - Revenue growth and Shoppers Drug Mart acquisition0:11:24 - Gross margin improvements and business strategy0:15:24 - Engagement with Canadian Pain Society0:19:56 - Research and development studies0:23:52 - Future growth potential in European and other markets0:25:48 - Explanation of audit filing delay#CannabisNews #CannabisEconomy #CannabisCommunity #MedicalMarijuana #MarijuanaStocks #CannabisInvestment #CannabisTrends #CBD #CannabisRescheduling #marijuanarescheduling Want to see the last week's recap?   • SNDL Headlines a Volatile Week in Can...  Want to see more Cannabis Reform videos?   • Can Cannabis Stocks Stay Resilient Am...  

Listen Now